Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 5/20 | 0.41 |
| ▸ | NOS1 | P29475 | 2/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 2/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30469665 | 1.00 | HTR7 (0.41) | HTR7NOS1NOS3HTR1ATGFBR1 | |
| SCHEMBL24364951 | 1.00 | HTR7 (0.41) | HTR7NOS1NOS3HTR1ATGFBR1 | |
| SCHEMBL30471013 | 0.92 | HTR7 (0.49) | HTR7NOS1HTR1ACHRNB4CHRNA3 | |
| SCHEMBL29343579 | 0.92 | HTR7 (0.49) | HTR7NOS1HTR1ACHRNB4CHRNA3 | |
| SCHEMBL29081809 | 0.92 | HTR7 (0.49) | HTR7NOS1HTR1ACHRNB4CHRNA3 | |
| SCHEMBL25321370 | 0.84 | HTR7 (0.45) | HTR7NOS1CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL25321361 | 0.84 | HTR7 (0.45) | HTR7NOS1CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL24366665 | 0.77 | NOTUM (0.40) | NOS1NOS3CHRNB4CHRNA3NOS2 | |
| SCHEMBL24364215 | 0.77 | CHRNB2 (0.47) | HTR7NOS1NOS2 | |
| SCHEMBL30470886 | 0.77 | CHRNB2 (0.47) | HTR7NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| CN-116568677-A | piperidin-1-yl-N-pyridin-3-yl-2-oxoacetamide derivatives useful for the treatment of MTAP deficiency and/or MTA accumulating cancers | 探戈医药股份有限公司 | 2023-08-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | HTR7 639/4885NOS1 1666/4885NOS3 2054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.